Evidence map›Paper›PMID 35091998›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

Current status and future perspectives in HER2 positive advanced gastric cancer.

G Roviello, M Catalano, L F Iannone, L Marano, M Brugia, G Rossi, G Aprile, L Antonuzzo

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. The impact of the PI3K/AKT/mTOR signaling pathway on trastuzumab resistance in HER2-positive gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Predictive biomarkers in gastric cancer.Journal of cancer research and clinical oncology · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

G RovielloDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.ORCID http://orcid.org/0000-0001-5504-8237
M CatalanoSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
L F IannoneDepartment of Health Science, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
L MaranoDepartment of Medical, Surgical and NeuroSciences, Section of Surgery, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
M BrugiaClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
G RossiClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
G AprileDepartment of Oncology, San Bortolo General Hospital, AULSS8 Berica, Vicenza, Italy.
L AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITUniversity of Florence · ITMagna Graecia University · ITOspedale San Bortolo · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease. HER2 expression is the main biomarker to lead the addition of trastuzumab to first line systemic chemotherapy improving the overall survival in advanced HER2-positivegastric adenocarcinoma. The inevitable development of resistance to trastuzumab remains a great problem inasmuch several treatment strategies that have proven effective in breast cancer failed to show clinical benefit in advanced gastric cancer. In this review, we summarize the available data on the mechanisms underlying primary and secondary resistance toHER2-targeted therapy and current challenges in the treatment of HER2-positive advanced gastric cancer refractory to trastuzumab. Further, we describe the prognostic value of new non-invasive screening techniques, the current development of novel agents such us HER2 antibody-drug conjugates and bispecific antibodies, and the strategies with antitumor activity on going.

Indexed as

AdenocarcinomaImmunoconjugatesStomach NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansTrastuzumabErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabAdvanced gastric cancerHER2HER2 resistanceTrastuzumab

Identifiers

PMID35091998
OpenAlexW4210277178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.